Discussion
Switching clotting factor products did not cause new inhibitors (neutralizing antibodies that can prevent the treatment from working) to develop in previously treated patients with moderate or severe hemophilia A or B who had no detectable inhibitors at the time of switching. That’s according to data from ATHN…